Evommune (NYSE:EVMN) Insider Janice Suzann Drew Sells 20,000 Shares of Stock

Evommune, Inc. (NYSE:EVMN) insider Janice Suzann Drew sold 20,000 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $22.63, for a total value of $452,600.00. Following the completion of the sale, the insider directly owned 67,794 shares of the company’s stock, valued at $1,534,178.22. The trade was a 22.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Evommune Price Performance

EVMN opened at $23.53 on Thursday. The company has a market capitalization of $847.59 million and a price-to-earnings ratio of -2.48. The firm’s fifty day moving average price is $23.07 and its two-hundred day moving average price is $22.28. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. As a group, equities analysts anticipate that Evommune, Inc. will post -2.85 EPS for the current year.

Institutional Trading of Evommune

Several hedge funds have recently added to or reduced their stakes in the stock. EQT Fund Management S.a r.l. bought a new position in shares of Evommune during the 4th quarter valued at approximately $84,395,000. RA Capital Management L.P. purchased a new stake in shares of Evommune during the 4th quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in shares of Evommune in the 4th quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in shares of Evommune in the 4th quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. purchased a new position in Evommune in the fourth quarter valued at approximately $22,408,000.

Analyst Upgrades and Downgrades

Several research firms have commented on EVMN. Stifel Nicolaus assumed coverage on shares of Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 target price on the stock. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Clear Str upgraded Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Morgan Stanley boosted their price objective on Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Oppenheimer began coverage on Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.